Loading clinical trials...
Loading clinical trials...
Sintilimab Combined With Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Single Arm Phase II Study
Conditions
Interventions
Sintilimab
Chidamide
Locations
1
China
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Start Date
November 1, 2019
Primary Completion Date
December 1, 2022
Completion Date
December 1, 2024
Last Updated
March 5, 2020
NCT06588868
NCT04128072
NCT04072458
NCT04447027
NCT05225584
NCT03493451
Lead Sponsor
Peking Union Medical College Hospital
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions